Use of amisulpride as an anti-emetic
View Patent ↗Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
1. A method for the prevention and/or treatment of post-operative nausea and vomiting, wherein said method comprises administering amisulpride racemate at a dose of 2.5 mg to 20 mg to a subject of a surgical procedure and in need of such prevention and/or treatment.
2. The method according to claim 1 , wherein the subject is also administered an emetogenic agent.
3. The method according to claim 2 , wherein the emetogenic agent is an opiate.
4. The method according to claim 2 , wherein the emetogenic agent is morphine.
5. The method according to claim 1 , wherein the amisulpride is administered by intravenous injection.
6. The method according to claim 1 , wherein the amisulpride is administered by intramuscular injection.
7. The method according to claim 1 , wherein the amisulpride is administered by subcutaneous injection.
8. The method according to claim 1 , wherein the subject is a human.
9. The method according to claim 1 , wherein the amisulpride is in the form of an acceptable pharmaceutical salt.
10. The method according to claim 1 , wherein the amisulpride is administered in combination with another anti-emetic drug.
11. The method according to claim 10 , wherein the another anti-emetic drug is a 5HT3 antagonist.
12. The method according to claim 11 , wherein the 5HT3 antagonist is ondansetron.
13. The method according to claim 1 , wherein the amisulpride is administered at a dose of 2.5 mg.
14. The method according to claim 1 , wherein the amisulpride is administered at a dose of 5 mg.
15. The method according to claim 1 , wherein the amisulpride is administered at a dose of 20 mg.
16. The method according to claim 1 , wherein the amisulpride is administered orally.
17. The method according to claim 1 , wherein the subject has received an anesthetic.
18. The method according to claim 1 , wherein the surgical procedure is chosen from procedures of the eye or ear, laparoscopic cholecystectomy, hysterectomy, breast surgery, abdominal surgery, and gynecological surgery.
19. A method for the prevention and/or treatment of post-operative nausea and vomiting, wherein said method comprises administering amisulpride racemate at a dose of 1 mg to 20 mg to a subject of a surgical procedure and in need of such prevention and/or treatment.
20. The method according to claim 19 , wherein the subject is also administered an emetogenic agent.
21. The method according to claim 20 , wherein the emetogenic agent is an opiate.
22. The method according to claim 20 , wherein the emetogenic agent is morphine.
23. The method according to claim 19 , wherein the amisulpride is administered by intravenous injection.
24. The method according to claim 19 , wherein the amisulpride is administered by intramuscular injection.
25. The method according to claim 19 , wherein the amisulpride is administered by subcutaneous injection.
26. The method according to claim 19 , wherein the subject is a human.
27. The method according to claim 19 , wherein the amisulpride is in the form of an acceptable pharmaceutical salt.
28. The method according to claim 19 , wherein the amisulpride is administered in combination with another anti-emetic drug.
29. The method according to claim 28 , wherein the another anti-emetic drug is a 5HT3 antagonist.
30. The method according to claim 29 , wherein the 5HT3 antagonist is ondansetron.
31. The method according to claim 19 , wherein the amisulpride is administered orally.
32. The method according to claim 19 , wherein the subject has received an anesthetic.
33. The method according to claim 19 , wherein the surgical procedure is chosen from procedures of the eye or ear, laparoscopic cholecystectomy, hysterectomy, breast surgery, abdominal surgery, and gynecological surgery.